All News
Prevalence and Mortality of IgG4-related disease in the USA
A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
Read Article
National Population Insights (4.28.2023)
Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.
Read Article
Links:
A Rising Gout Risk in Asians
Two independent data sets suggests the prevalence of gout among Asians has grown such that this sub-population has numerically surpassed all other racial and ethnic groups by 2018.
Read Article
Want to Go Far, Go Together (4.21.2023)
This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.
Read Article
Amgen Wins Otezla Patent Case - Brand Protected till 2028
Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.
Read Article
TNR: Private Practice & Academia
In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?".
Read Article
The Match Game (4.14.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
Read Article
Pain and Opioid Updates
Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids.
MMWR April 14, 2023
Read Article
Links:
Industry Payments to Rheumatologists Dropped During COVID
Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.
Read Article
Rheumatologist - Work-Life Survey Results
During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
Read Article
British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline
British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
Read Article
Gout - Hot Topics in March 2023
A number of new reports this month shed new light on old issues in Gout.
Read Article
Polypharmacy Increased in Psoriatic Arthritis
Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
Read Article
Carpal Tunnel - Steroid injection vs. Night Splinting
A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.
Read Article
Big Time Vasculitis (3.10.2023)
Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?
Read Article
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
Read Article
Treat-to-Target Guidelines for GCA and PMR
The Annals of Rheumatic Disease has published updated multinational, treat-to-target (T2T) recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Read Article
New Drug Formulations – For Patients or Profits?
Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.
Read Article